KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Depreciation and Depletion: 2018-2025

Historic Depreciation and Depletion for Castle Biosciences (CSTL) over the last 8 years, with Sep 2025 value amounting to $1.5 million.

  • Castle Biosciences' Depreciation and Depletion rose 21.36% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year increase of 32.70%. This contributed to the annual value of $4.9 million for FY2024, which is 47.45% up from last year.
  • Castle Biosciences' Depreciation and Depletion amounted to $1.5 million in Q3 2025, which was up 5.99% from $1.5 million recorded in Q2 2025.
  • Over the past 5 years, Castle Biosciences' Depreciation and Depletion peaked at $1.5 million during Q3 2025, and registered a low of $233,000 during Q1 2021.
  • Moreover, its 3-year median value for Depreciation and Depletion was $1.1 million (2024), whereas its average is $1.1 million.
  • Data for Castle Biosciences' Depreciation and Depletion shows a peak YoY surged of 270.59% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Castle Biosciences' Depreciation and Depletion stood at $442,000 in 2021, then skyrocketed by 41.86% to $627,000 in 2022, then surged by 51.99% to $953,000 in 2023, then surged by 49.84% to $1.4 million in 2024, then climbed by 21.36% to $1.5 million in 2025.
  • Its Depreciation and Depletion was $1.5 million in Q3 2025, compared to $1.5 million in Q2 2025 and $1.4 million in Q1 2025.